{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:33:19Z","timestamp":1784950399491,"version":"3.55.0"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Respiratory syncytial virus (RSV) infection is the leading cause of infant hospitalizations in the US. Two immunization options are available to protect infants against hospitalization\u2014maternal vaccination during pregnancy or RSV antibody shot administration for infants after birth. Gaps in immunization coverage suggest missed opportunities to protect infants against RSV-associated hospitalization.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To describe RSV immunization intentions, behaviors, and preferences among pregnant women and parents of young children (ages 0-5 years).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n For this survey study, 2 concurrent national cross-sectional surveys were implemented in April 2024. Participants were recruited from a representative online survey panel of US adults. Participants were 18 years or older and either pregnant or the parent of a young child. Data were analyzed from May to November 2025.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The outcomes of interest were prevalence of positive intention to receive RSV antibody shot for child among pregnant women and parents and prevalence of positive intention to receive RSV maternal vaccine among pregnant women.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 1765 parents and 174 pregnant women, most were aged 30 years or older (parent: 78.1% [95% CI, 76.2%-80.0%]; pregnant women: 64.0% [95% CI, 56.8%-71.1%]). Among pregnant women eligible for vaccination, 55.5% (95% CI, 47.7%-63.3%) reported a positive intention toward maternal RSV vaccination. Among pregnant women with negative or unsure intention, 35.8% (95% CI, 24.3%-47.3%) would probably or definitely accept RSV vaccination following a strong health care practitioner recommendation. Among parents, 59.8% (95% CI, 57.5%-62.1%) reported a positive intention toward RSV antibody shot administration for their child. Among parents with negative or unsure intention, 27.0% (95% CI, 23.7%-30.2%) would probably or definitely accept the RSV antibody shot for their child following a strong health care practitioner recommendation. More participants preferred maternal vaccination (parents: 48.3% [95% CI, 46.0%-50.6%]; pregnant women: 58.2% (95% CI, 50.9%-65.6%]) over infant RSV antibody shot administration (parents: 9.4% (95% CI, 8.1%-10.8%]; pregnant women: 6.2% (95% CI, 2.6%-9.8%). Top reasons for negative or unsure intentions in both groups included lack of information and safety concerns.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this survey study, pregnant women and parents of young children preferred maternal RSV vaccination for protecting infants against RSV infection. For some participants with negative or unsure intentions about RSV immunization, a strong health care practitioner recommendation shifted intention toward accepting immunization. Future research efforts should design and evaluate novel communication strategies for providing information about RSV immunization options to eligible families, in addition to strengthening health care practitioner recommendation in favor of immunization.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.25117","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:30:19Z","timestamp":1784907019000},"page":"e2625117","source":"Crossref","is-referenced-by-count":1,"title":["Respiratory Syncytial Virus Immunization Intention During Pregnancy and Infancy"],"prefix":"10.1001","volume":"9","author":[{"given":"Rachael M.","family":"Porter","sequence":"first","affiliation":[{"name":"Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Campos","sequence":"additional","affiliation":[{"name":"Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Shoaib","sequence":"additional","affiliation":[{"name":"Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara M.","family":"Vogt","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Orenstein","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pediatrics, Epidemiology and Global Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Bednarczyk","sequence":"additional","affiliation":[{"name":"Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavanya","family":"Vasudevan","sequence":"additional","affiliation":[{"name":"Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"zoi260701r1","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1093\/infdis\/jiac120","article-title":"Respiratory syncytial virus is the leading cause of United States infant hospitalizations, 2009-2019: a study of the National (Nationwide) Inpatient Sample.","volume":"226","author":"Suh","year":"2022","journal-title":"J Infect Dis"},{"issue":"6","key":"zoi260701r2","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/infdis\/jiaa752","article-title":"Respiratory syncytial virus-associated hospitalization rates among US infants: a systematic review and meta-analysis.","volume":"225","author":"McLaughlin","year":"2022","journal-title":"J Infect Dis"},{"issue":"2","key":"zoi260701r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0527","article-title":"Mortality associated with influenza and respiratory syncytial virus in the US, 1999-2018.","volume":"5","author":"Hansen","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi260701r4","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1542\/peds.2013-0303","article-title":"Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age.","volume":"132","author":"Hall","year":"2013","journal-title":"Pediatrics"},{"issue":"14","key":"zoi260701r6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.15585\/mmwr.mm7214a1","article-title":"Seasonality of respiratory syncytial virus\u2014United States, 2017-2023.","volume":"72","author":"Hamid","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"41","key":"zoi260701r7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.15585\/mmwr.mm7241e1","article-title":"Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023.","volume":"72","author":"Fleming-Dutra","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"34","key":"zoi260701r8","doi-asserted-by":"publisher","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023.","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"32","key":"zoi260701r12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.15585\/mmwr.mm7432a3","article-title":"Use of clesrovimab for prevention of severe respiratory syncytial virus-associated lower respiratory tract infections in infants: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2025.","volume":"74","author":"Moulia","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"16","key":"zoi260701r13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.15585\/mmwr.mm7416a1","article-title":"Interim evaluation of respiratory syncytial virus hospitalization rates among infants and young children after introduction of respiratory syncytial virus prevention products\u2014United States, October 2024-February 2025.","volume":"74","author":"Patton","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"zoi260701r14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","article-title":"Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus-associated hospitalization among infants entering their first respiratory syncytial virus season\u2014New Vaccine Surveillance Network, October 2023-February 2024.","volume":"73","author":"Moline","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"31","key":"zoi260701r15","doi-asserted-by":"publisher","first-page":"484","DOI":"10.15585\/mmwr.mm7431a3","article-title":"Respiratory syncytial virus immunization coverage among infants through receipt of nirsevimab monoclonal antibody or maternal vaccination\u2014United States, October 2023-March 2024.","volume":"74","author":"Boundy","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"zoi260701r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.20667","article-title":"Vaccination intentions during pregnancy and among parents of young children.","volume":"8","author":"Vasudevan","year":"2025","journal-title":"JAMA Netw Open"},{"key":"zoi260701r18","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1467","article-title":"1633. Willingness to receive maternal RSV vaccine and infant monoclonal RSV antibody.","volume":"10","author":"Gidengil","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"39","key":"zoi260701r19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.15585\/mmwr.mm7239a4","article-title":"Influenza, Tdap, and COVID-19 vaccination coverage and hesitancy among pregnant women\u2014United States, April 2023.","volume":"72","author":"Razzaghi","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"29","key":"zoi260701r20","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1016\/j.vaccine.2023.05.047","article-title":"Vaccine hesitancy in pregnant women: a narrative review.","volume":"41","author":"Mitchell","year":"2023","journal-title":"Vaccine"},{"issue":"8","key":"zoi260701r21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061477","article-title":"COVID-19 vaccine hesitancy among pregnant women: a systematic review and meta-analysis.","volume":"12","author":"Bhattacharya","year":"2022","journal-title":"BMJ Open"},{"issue":"2","key":"zoi260701r22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.pcl.2022.11.004","article-title":"Maternal vaccination and vaccine hesitancy.","volume":"70","author":"Rand","year":"2023","journal-title":"Pediatr Clin North Am"},{"key":"zoi260701r5","author":"US Centers for Disease Control and Prevention","year":"2025"},{"key":"zoi260701r9","unstructured":"Centers for Disease Control and Prevention. Child and adolescent immunization schedule by age. Updated August 7, 2025. Accessed December 3, 2025. https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/child-adolescent-age.html"},{"key":"zoi260701r10","unstructured":"Jenco? M. FDA approves new monoclonal antibody to protect infants from RSV. AAP News. June 10, 2025. Accessed December 3, 2025. https:\/\/publications.aap.org\/aapnews\/news\/32373\/FDA-approves-new-monoclonal-antibody-to-protect?autologincheck=redirected"},{"key":"zoi260701r11","unstructured":"Centers for Disease Control and Prevention. ACIP recommendations. News release. August 8, 2025. Accessed December 3, 2025. https:\/\/www.cdc.gov\/acip\/vaccine-recommendations\/index.html"},{"key":"zoi260701r17","unstructured":"Ipsos. KnowledgePanel sampling and weighting methodology. Accessed December 3, 2025. https:\/\/www.ipsos.com\/sites\/default\/files\/kpsamplingandweighting.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2852070\/porter_2026_oi_260701_1784306792.91287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:30:20Z","timestamp":1784907020000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2852070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.25117","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}